NKTX
Nkarta IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$204.62M
P/E Ratio
—
EPS
$-1.35
Beta
0.90
52W High
$3.65
52W Low
$1.63
50-Day MA
$2.83
200-Day MA
$2.29
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 385 |
| Gross Profit (TTM) | $-36.22M |
| EBITDA | $-106.03M |
| Operating Margin | 0.00% |
| Return on Equity | -30.10% |
| Return on Assets | -17.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.01 |
| Price-to-Book | 0.72 |
| Price-to-Sales (TTM) | 1000000.00 |
| EV/Revenue | 1000000.0 |
| EV/EBITDA | 0.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.55M |
| Float | $60.45M |
| % Insiders | 4.88% |
| % Institutions | 80.55% |
Historical Volatility
HV 10-Day
101.65%
HV 20-Day
84.63%
HV 30-Day
83.40%
HV 60-Day
90.26%
HV Rank
82.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.20 target)
1
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026